[go: up one dir, main page]

LU90865I2 - Hydrochlorure d sibutramine ses d-riv-s et ses sels pharmaceutiquement acceptables en particulier le monohydrate d'hydrochlorure de sibutramine - Google Patents

Hydrochlorure d sibutramine ses d-riv-s et ses sels pharmaceutiquement acceptables en particulier le monohydrate d'hydrochlorure de sibutramine

Info

Publication number
LU90865I2
LU90865I2 LU90865C LU90865C LU90865I2 LU 90865 I2 LU90865 I2 LU 90865I2 LU 90865 C LU90865 C LU 90865C LU 90865 C LU90865 C LU 90865C LU 90865 I2 LU90865 I2 LU 90865I2
Authority
LU
Luxembourg
Prior art keywords
sibutramine hydrochloride
riv
pharmaceutically acceptable
acceptable salts
monohydrate
Prior art date
Application number
LU90865C
Other languages
English (en)
Original Assignee
Knoll Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10589895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU90865(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Knoll Ag filed Critical Knoll Ag
Publication of LU90865I2 publication Critical patent/LU90865I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
LU90865C 1985-12-17 2001-12-18 Hydrochlorure d sibutramine ses d-riv-s et ses sels pharmaceutiquement acceptables en particulier le monohydrate d'hydrochlorure de sibutramine LU90865I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB858531071A GB8531071D0 (en) 1985-12-17 1985-12-17 Therapeutic compound

Publications (1)

Publication Number Publication Date
LU90865I2 true LU90865I2 (fr) 2002-02-18

Family

ID=10589895

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90865C LU90865I2 (fr) 1985-12-17 2001-12-18 Hydrochlorure d sibutramine ses d-riv-s et ses sels pharmaceutiquement acceptables en particulier le monohydrate d'hydrochlorure de sibutramine

Country Status (34)

Country Link
US (2) US4929629A (fr)
EP (1) EP0230742B1 (fr)
JP (1) JPS62155240A (fr)
KR (1) KR940008913B1 (fr)
CN (1) CN1016245B (fr)
AT (1) ATE56942T1 (fr)
AU (1) AU601167B2 (fr)
CA (1) CA1266278A (fr)
CS (1) CS259545B2 (fr)
DD (1) DD263050A5 (fr)
DE (1) DE3674570D1 (fr)
DK (1) DK170770B1 (fr)
EG (1) EG17770A (fr)
ES (1) ES2018163T4 (fr)
FI (1) FI90413C (fr)
GB (1) GB8531071D0 (fr)
GE (1) GEP19970812B (fr)
GR (1) GR3001069T3 (fr)
HU (1) HU201901B (fr)
IE (1) IE59429B1 (fr)
IL (1) IL80934A (fr)
IN (1) IN163129B (fr)
LU (1) LU90865I2 (fr)
MX (1) MX4684A (fr)
NL (1) NL300065I1 (fr)
NO (2) NO165540C (fr)
NZ (1) NZ218578A (fr)
PH (1) PH22481A (fr)
PL (1) PL149519B1 (fr)
PT (1) PT83958B (fr)
SU (1) SU1443796A3 (fr)
UA (1) UA7206A1 (fr)
YU (1) YU46033B (fr)
ZA (1) ZA869078B (fr)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
WO1994000114A1 (fr) * 1992-06-23 1994-01-06 Sepracor Inc. Procedes et compositions utilises pour traiter la depression et d'autres affections avec de la sibutramine (-) optiquement pure
EP0708639A4 (fr) * 1992-06-23 1997-08-20 Sepracor Inc Procedes et compositions utilises pour traiter la depression et d'autres affections avec de la sibutramine (+) optiquement pure
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
DE4443891A1 (de) 1994-12-09 1996-06-13 Bayer Ag Heterocyclisch substituierte Oxy-phenyl-(phenyl)glycinolamide
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
GB9619961D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9619962D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6974838B2 (en) * 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
CZ20012662A3 (cs) * 1999-01-20 2002-08-14 Knoll Gmbh Léčivo pro léčbu symptomů odvykání kouření
BG65170B1 (bg) * 1999-03-17 2007-05-31 Knoll Gmbh Използване на n-заместени производни на 1-[1-(4-хлорофенил)циклобутил]-3-метилбутиламин за производство на лекарство за лечение на разстройства при храненето
WO2000056315A1 (fr) * 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Traitement de la douleur
US6803387B1 (en) 1999-03-19 2004-10-12 Abbott Gmbh & Co. Kg Treatment of neuropathic pain or fibromyalgia
AU3899100A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Treatment of hyperactivity disorders
WO2000056311A1 (fr) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Regulation du metabolisme
HK1044462B (en) 1999-03-19 2006-03-03 Abbott Gmbh & Co. Kg Use of sibutramine or its derivative for the treatment of sleep disorders
WO2000056310A1 (fr) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Traitement du syndrome de fatigue chronique
WO2000056308A1 (fr) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Prevention de maladies cardio-vasculaires
AU3757200A (en) 1999-03-19 2000-10-09 Knoll Gmbh Treatment of pulmonary hypertension
WO2000056319A1 (fr) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Traitement de l'hypotension orthostatique
MXPA01009470A (es) * 1999-03-19 2004-03-19 Knoll Gmbh Tratamiento de ciertos canceres asociados con el aumento de peso.
CA2366660A1 (fr) * 1999-03-19 2000-09-28 Carl M. Mendel Traitement de l'arthrose
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
WO2000056309A1 (fr) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Procede de traitement de troubles de la sexualite
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6380200B1 (en) 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
US6562974B2 (en) 2000-02-01 2003-05-13 The Procter & Gamble Company Process for making geminal bisphosphonates
US6410520B2 (en) 2000-02-01 2002-06-25 The Procter & Gamble Company Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1, 1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate
US6232347B1 (en) 2000-03-17 2001-05-15 Knoll Pharmaceutical Company Treatment of osteoarthritis
US6610887B2 (en) * 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
CA2478183C (fr) * 2002-03-12 2010-02-16 Merck & Co. Inc. Amides substitues
HRP20050307A2 (en) * 2002-10-05 2006-12-31 Hanmi Pharm. Co. Ltd. Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate
KR100536750B1 (ko) * 2002-10-05 2005-12-16 한미약품 주식회사 시부트라민 메탄술폰산염의 결정성 반수화물을 포함하는약학 조성물
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
GB0310361D0 (en) * 2003-05-06 2003-06-11 Cipla Ltd Pharmaceutical compound
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
EP1819681B1 (fr) * 2004-11-23 2009-08-12 Warner-Lambert Company LLC Derives d'acide 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoique comme inhibiteurs de hmg co-a reductase pour le traitement de l'hyperlipidemie
KR100830002B1 (ko) 2005-01-06 2008-05-15 씨제이제일제당 (주) 시부트라민의 무기산염
US8283312B2 (en) * 2005-02-04 2012-10-09 The Research Foundation Of State University Of New York Compositions and methods for modulating body weight and treating obesity-related disorders
KR100781882B1 (ko) * 2005-07-12 2007-12-05 주식회사유한양행 시부트라민을 함유하는 약제학적 조성물
JP2009503050A (ja) * 2005-08-04 2009-01-29 ファイザー・リミテッド ピペリジノイル−ピロリジンおよびピペリジノイル−ピペリジン化合物
JPWO2007034910A1 (ja) * 2005-09-22 2009-03-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 過食症及び過食症に伴ううつ病の治療用医薬組成物
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
RS20080371A (sr) * 2006-02-23 2009-07-15 Pfizer Limited, Piperidinoilpirolodini agonisti receptora melanokortina tipa 4
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
RU2462451C2 (ru) 2006-09-15 2012-09-27 Ривайва Фармасьютикалс, Инк. Способ получения, способы применения и композиции циклоалкилметиламинов
US8604244B2 (en) 2010-07-02 2013-12-10 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
MX2009004314A (es) 2006-11-13 2009-05-05 Pfizer Prod Inc Diaril, dipiridinil y arilpiridinilderivados y usos de los mismos.
AU2007323193A1 (en) * 2006-11-20 2008-05-29 Glenmark Pharmaceuticals S.A. Acetylene derivatives as Stearoyl CoA Desaturase inhibitors
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
US20080221057A1 (en) * 2007-02-16 2008-09-11 Wyeth Secreted protein ccdc80 regulates adipocyte differentiation
WO2008124122A1 (fr) * 2007-04-09 2008-10-16 Scidose, Llc Combinaisons de statines, d'agent anti-obésité et de glitazones
WO2008124120A1 (fr) * 2007-04-09 2008-10-16 Scidose, Llc Combinaisons de statines et d'agent anti-obésité
WO2009037542A2 (fr) 2007-09-20 2009-03-26 Glenmark Pharmaceuticals, S.A. Composés spirocycliques en tant qu'inhibiteurs de stéaroyle coa désaturase
WO2010015972A1 (fr) * 2008-08-06 2010-02-11 Pfizer Limited Composés diazépines et diazocanes en tant qu'agonistes de mc4
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
WO2010093243A1 (fr) 2009-02-12 2010-08-19 Coöperatieve Mirzorg U.A., Arnhem Utilisation d'une combinaison de diazoxyde et de metformine pour le traitement de l'obésité ou des troubles liés à l'obésité
CA2777857C (fr) 2009-11-02 2014-12-02 Pfizer Inc. Derives dioxa-bicyclo[3.2.1]octane-2,3,4-triol
EP2554168B1 (fr) 2010-03-29 2018-01-24 Astellas Pharma Inc. Composition pharmaceutique à libération contrôlée
WO2012004588A2 (fr) 2010-07-06 2012-01-12 Astrazeneca Ab Agents thérapeutiques 976
SI3023102T1 (sl) 2010-11-04 2018-11-30 Albireo Ab IBAT inhibitorji za zdravljenje jetrnih bolezni
CN103228270B (zh) 2010-11-08 2016-02-10 阿尔比里奥公司 含ibat抑制剂和胆汁酸结合剂的药物组合
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
WO2014036528A2 (fr) 2012-08-31 2014-03-06 Ixchel Pharma, Llc Agents utiles pour le traitement de l'obésité, du diabète et de troubles associés
CN110372522B (zh) * 2019-07-30 2020-10-02 南京工业大学 一种从含有戊二胺的固相中汽提回收戊二胺的方法
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1124485B (de) * 1960-02-12 1962-03-01 Hoechst Ag Verfahren zur Herstellung von analeptisch wirksamen Phenylcycloalkylmethylaminen
SE7600674L (sv) * 1975-02-05 1976-08-06 Rohm & Haas Fungicider
ZA821577B (en) * 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
US4443449A (en) * 1981-04-06 1984-04-17 The Boots Company Limited Arylcyclobutylalkylamines and anti-depression composition and methods using same
GB2115409B (en) * 1982-02-24 1985-08-07 Zyma Sa Novel crystal modifications of (+)-catechin
DK101683A (da) * 1982-03-12 1983-09-13 Duphar Int Res Phenylpiperazinderivater og fremgangsmaade til fremstilling heraf
IE56001B1 (en) * 1982-09-30 1991-03-13 Boots Co Plc 1-arylcyclobutylmethylamine compounds
IE56000B1 (en) * 1982-09-30 1991-03-13 Boots Co Plc 1-arylcyclobutylalkylamine compounds
ZA836848B (en) * 1982-09-30 1984-05-30 Boots Co Plc Therapeutic agents
GB8501192D0 (en) * 1985-01-17 1985-02-20 Boots Co Plc Therapeutic agents
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity

Also Published As

Publication number Publication date
HUT45964A (en) 1988-09-28
YU46033B (sh) 1992-12-21
NZ218578A (en) 1989-04-26
US4929629A (en) 1990-05-29
ATE56942T1 (de) 1990-10-15
JPH0144176B2 (fr) 1989-09-26
IL80934A (en) 1990-07-26
NO865093L (no) 1987-06-18
UA7206A1 (uk) 1995-06-30
EP0230742B1 (fr) 1990-09-26
NO865093D0 (no) 1986-12-16
DE3674570D1 (de) 1990-10-31
DK585786A (da) 1987-06-18
NO165540C (no) 1991-02-27
KR940008913B1 (ko) 1994-09-28
US5068440A (en) 1991-11-26
ZA869078B (en) 1987-07-29
CA1266278A (fr) 1990-02-27
GR3001069T3 (en) 1992-03-20
SU1443796A3 (ru) 1988-12-07
FI90413C (fi) 1994-02-10
CS930586A2 (en) 1988-02-15
EG17770A (en) 1991-03-30
FI90413B (fi) 1993-10-29
ES2018163T4 (es) 2012-06-14
AU6644286A (en) 1987-06-18
NO165540B (no) 1990-11-19
IN163129B (fr) 1988-08-13
IE863102L (en) 1987-06-17
GEP19970812B (en) 1997-02-10
NO2005022I1 (no) 2005-10-03
HU201901B (en) 1991-01-28
NL300065I1 (nl) 2001-12-01
PH22481A (en) 1988-09-12
MX4684A (es) 1993-12-01
CN86108547A (zh) 1987-08-19
EP0230742A1 (fr) 1987-08-05
DD263050A5 (de) 1988-12-21
AU601167B2 (en) 1990-09-06
PT83958A (en) 1987-01-01
PT83958B (pt) 1989-05-12
ES2018163B3 (es) 1991-04-01
PL149519B1 (en) 1990-02-28
GB8531071D0 (en) 1986-01-29
FI865030A0 (fi) 1986-12-10
IE59429B1 (en) 1994-02-23
PL263020A1 (en) 1988-05-12
JPS62155240A (ja) 1987-07-10
YU205086A (en) 1987-12-31
DK170770B1 (da) 1996-01-15
CN1016245B (zh) 1992-04-15
CS259545B2 (en) 1988-10-14
DK585786D0 (da) 1986-12-05
FI865030L (fi) 1987-06-18
KR870005961A (ko) 1987-07-08

Similar Documents

Publication Publication Date Title
LU90865I2 (fr) Hydrochlorure d sibutramine ses d-riv-s et ses sels pharmaceutiquement acceptables en particulier le monohydrate d'hydrochlorure de sibutramine
LU90866I2 (fr) Hydrochlorure de sibutramine ses d-riv-s et ses sels pharmaceutiquement acceptables en particulier le monohydrate d'hydrochlorurede sibutramine
LU91131I2 (fr) Duloxétine et ses sels d'addition acides pharmaceutiquement acceptables, et en particulier, chlorhydrate de duloxétine.
IT8567165A1 (it) Composizioni a base di liposomi, particolarmente per mantenere ed immobilizzare una riserva di agenti biologicamente attivi, e relativo procedimento d'impiego.
MY101593A (en) Sustained release preparation.
DE3587587D1 (de) N-Acetylneuraminsäure enthaltende Expektorantien.
GR3001862T3 (en) Pharmaceutical preparation for tinea pedis
ATE81775T1 (de) Pharmazeutische zusammensetzungen.
NZ221596A (en) N-(2-(4-carboxymethoxyphenyl)-1-(r)-1-methylethyl)-2-(r)-2- hydroxy-2-(3-chlorophenyl)ethanamine optionally with the ss-isomer also, and pharmaceutical and veterinary uses
DK730488A (da) Synergistisk kombination af decarboxylasehaemmere og l-dopa-pellets
FR2541113B1 (fr) Application therapeutique de la n-methyl-n-bis (3,4-dimethoxyphenylethyl) amine et de ses sels d'addition avec des acides pharmaceutiquement acceptables
IT216623Z2 (it) Fermaglio di estremita' del cerchietto in nastro di acciaio.
GB1454390A (en) Nasal decongestants